Tome Biosciences emerged from stealth with $213 million in financing and plans to create curative cell and gene therapies that correct genes in vivo. The company’s programmable genomic integration technology enables the insertion of any DNA sequence into any programmed genomic location. Initial projects include gene therapies for monogenic liver diseases and cell therapies for autoimmune diseases. The company, which has almost 150 employees, plans to disclose clinical indications for its first therapies in 2024.
FDA Wraps Up 2024 Handing Out Several Notable Regulatory Decisions
The FDA has had a busy December 2025, with several notable new drug approvals. Eli Lilly’s Zepbound became the first FDA-approved medicine for chronic sleep
